Apr 05, 2012, 10.58 PM | Source: CNBC-TV18

Biocon expands its R&D facility in Bangalore

Bio-pharma major Biocon on expansion mode.

Kiran Mazumdar-Shaw, CMD, Biocon
Bio-pharma major Biocon is on an expansion mode. The biotech major plans to invest close to Rs 100 crore on its new research and development center located in Bangalore, with a window for future investments going up to Rs 200 crore in next few years.

Biocon is banking on a strong research pipeline. The company's focus on oral insulin will continue.
Kiran Mazumdar-Shaw, chairman and managing director, Biocon
says, the big change in our strategy would be that from having one global partner which was Pfizer, we'll have multiple partners.

Biocon stock price

On November 26, 2015, at 14:35 hrs Biocon was quoting at Rs 461.30, up Rs 6.90, or 1.52 percent. The 52-week high of the share was Rs 495.70 and the 52-week low was Rs 396.50.

The company's trailing 12-month (TTM) EPS was at Rs 35.36 per share as per the quarter ended September 2015. The stock's price-to-earnings (P/E) ratio was 13.05. The latest book value of the company is Rs 129.18 per share. At current value, the price-to-book value of the company is 3.57.

Set email alert for


video of the day

Nifty to fall below 7500 if Q3 disappoints; GST key: Kumar

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.